Evidence map›Paper›PMID 36153426›Full record

ArticleScientific reports2022

Lead-exposure associated miRNAs in humans and Alzheimer's disease as potential biomarkers of the disease and disease processes.

Qingfeng Wen, Marcha Verheijen, Mandy Melissa Jane Wittens, Julia Czuryło, Sebastiaan Engelborghs, Duncan Hauser, Marcel H M van Herwijnen, Thomas Lundh, Ingvar A Bergdahl, Soterios A Kyrtopoulos and 4 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 4 countries.

Qingfeng WenDepartment of Toxicogenomics, Maastricht University, Universiteitssingel 50, 6229 ER, Maastricht, The Netherlands. q.wen@maastrichtuniversity.nl.
Marcha VerheijenDepartment of Toxicogenomics, Maastricht University, Universiteitssingel 50, 6229 ER, Maastricht, The Netherlands.
Mandy Melissa Jane WittensDepartment of Biomedical Sciences, Institute Born-Bunge, University of Antwerp, Universiteitsplein 1, 2610, Antwerpen, Belgium.
Julia CzuryłoDepartment of Toxicogenomics, Maastricht University, Universiteitssingel 50, 6229 ER, Maastricht, The Netherlands.
Sebastiaan EngelborghsDepartment of Biomedical Sciences, Institute Born-Bunge, University of Antwerp, Universiteitsplein 1, 2610, Antwerpen, Belgium.
Duncan HauserDepartment of Toxicogenomics, Maastricht University, Universiteitssingel 50, 6229 ER, Maastricht, The Netherlands.
Marcel H M van HerwijnenDepartment of Toxicogenomics, Maastricht University, Universiteitssingel 50, 6229 ER, Maastricht, The Netherlands.
Thomas LundhDivision of Occupational and Environmental Medicine, Lund University Hospital, Lund, Sweden.
Ingvar A BergdahlSection of Sustainable Health, Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden.
Soterios A KyrtopoulosInstitute of Chemical Biology, National Hellenic Research Foundation, Athens, Greece.
Theo M de KokDepartment of Toxicogenomics, Maastricht University, Universiteitssingel 50, 6229 ER, Maastricht, The Netherlands.
Hubert J M SmeetsDepartment of Toxicogenomics, Maastricht University, Universiteitssingel 50, 6229 ER, Maastricht, The Netherlands.
Jacco Jan BriedéDepartment of Toxicogenomics, Maastricht University, Universiteitssingel 50, 6229 ER, Maastricht, The Netherlands.
Julian KrauskopfDepartment of Toxicogenomics, Maastricht University, Universiteitssingel 50, 6229 ER, Maastricht, The Netherlands.
Maastricht University · NLLund University · SENational Hellenic Research Foundation · GRUmeå University · SEUniversitair Ziekenhuis Brussel · BEVrije Universiteit Brussel · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's disease (AD) is a neurodegenerative disease that eventually affects memory and behavior. The identification of biomarkers based on risk factors for AD provides insight into the disease since the exact cause of AD remains unknown. Several studies have proposed microRNAs (miRNAs) in blood as potential biomarkers for AD. Exposure to heavy metals is a potential risk factor for onset and development of AD. Blood cells of subjects that are exposed to lead detected in the circulatory system, potentially reflect molecular responses to this exposure that are similar to the response of neurons. In this study we analyzed blood cell-derived miRNAs derived from a general population as proxies of potentially AD-related mechanisms triggered by lead exposure. Subsequently, we analyzed these mechanisms in the brain tissue of AD subjects and controls. A total of four miRNAs were identified as lead exposure-associated with hsa-miR-3651, hsa-miR-150-5p and hsa-miR-664b-3p being negatively and hsa-miR-627 positively associated. In human brain derived from AD and AD control subjects all four miRNAs were detected. Moreover, two miRNAs (miR-3651, miR-664b-3p) showed significant differential expression in AD brains versus controls, in accordance with the change direction of lead exposure. The miRNAs' gene targets were validated for expression in the human brain and were found enriched in AD-relevant pathways such as axon guidance. Moreover, we identified several AD relevant transcription factors such as CREB1 associated with the identified miRNAs. These findings suggest that the identified miRNAs are involved in the development of AD and might be useful in the development of new, less invasive biomarkers for monitoring of novel therapies or of processes involved in AD development.

Indexed as

Alzheimer DiseaseMicroRNAsNeurodegenerative DiseasesBiomarkersHumansLeadTranscription FactorsBiomarkersLeadMicroRNAsTranscription Factors

Identifiers

PMID36153426
PMCPMC9509380
OpenAlexW4297183188

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.